Renal denervation: Brightest hope since angioplasty?

January 4, 2013 - Cardiovascular Business

Renal sympathetic denervation is an emerging technique for treating drug-resistant hypertension, a significant problem globally. The therapy presents real hope, not only in offering a possible solution to the significant and stubborn problem of resistant hypertension, but potentially also in treating sleep apnea, heart failure and diabetes. Only extensive research and time will tell whether renal denervation is the best innovation since angioplasty or a niche therapy. Early indications are promising. more


TransCorp Spine patient testimonials

January 3, 2013 - YouTube

MAF-1 portfolio company TransCorp Spine has posted a video of patient and caregiver testimonials about the SpinePort MIS Access System for a TransCorporeal MicroDecompression procedure. This minimally-invasive procedure accesses the cervical spine from an anterior approach. It utilizes the latest technology providing targeted access to the offending pathology, for removal of the herniation or fragmentation and decompression of the spinal cord and nerve. more


MAF-1 portfolio company TransCorp Spine receives national peer-review award

December 25, 2012 - Grand Rapids Business Journal

The SpinePort surgical system has received a 2012 Spine Tech Award from the trade publication Orthopedics This Week. The 2012 Spine Tech Award in the cervical, neck category was presented to TransCorp Spine, an Ada-based Michigan Accelerator Fund I portfollio company that markets the SpinePort. The publication’s annual awards are determined by a peer-review process and recognize the best products, engineers and inventors in spine surgery. more


TransCorp Spine recognized as one of top ten best new spine technologies of 2012

The winners of the 2012 
Orthopedics This Week Best Technology Award for Spine are Biomet, Inc., ISTO Technologies, Inc., Medtronic Spine and Biologics, Mighty Oak Medical, NuVasive, Inc., Safewire, LLC, Society for Minimally Invasive Surgery (SMISS) and TransCorp Spine. The Orthopedics This Week Spine Technology Award is meant to reward inventors, engineering teams and surgeons who create the most innovative, enduring and practical products to treat back pain or instability. The TransCorp Spine SpinePort™ System provides anterior approach access to, and decompression of, cervical spinal elements in a minimally invasive manner by using the SpinePort guide system to create a 6mm channel along a precisely controlled trajectory within and across a single vertebral body from the anterior to the posterior surface of that body, without violating endplates or the disc and thereby retaining all natural motion within the spine and minimizing disruption of natural anatomy overall.  more

Beating fundraising goal opens more options for MAF-1

October 13, 2012 - MiBiz

After closing fundraising on its flagship fund to invest more than $15.1 million in early stage Michigan-based businesses, Michigan Accelerator Fund I can now focus on building its investment portfolio and recording its first exit. The amount raised by the two-year-old fund is 50 percent more than originally targeted, an indication of growing awareness among high-net worth individuals and institutional investors on the viability of venture investing in the marketplace, the fund’s Co-Managing Director Dale Grogan said.

“There is an unmet need there,” Grogan said. “We’ve just seen in the last two years where the level of education and understanding has gone up substantially as it relates to venture investing and access to capital.” more



Two Michigan companies share innovator award

September 27, 2012 - Oakland County News

A Southfield company that created a device to alert doctors when nerves are at risk of injury during surgery and a Kalamazoo company whose technology treats hypertension were chosen as Medical Main Street "Innovators of the Year." The companies, Sentio LLC of Southfield, and Ablative Solutions Inc, of Kalamazoo, were honored on Oct. 4 during the INNO-VENTION 2012 medical device conference. "These two companies are creating the types of medical devices that save peoples' lives," Oakland County Executive L. Brooks Patterson said. "I can't think of two companies more deserving of this inaugural Innovator of the Year award. The technology they employ fits perfectly on Medical Main Street." more


MAF-1 Portfolio Company Ablative Solutions receives Innovator of the Year Award

September 21, 2012 - Crain's Detroit Business

Two state companies, Sentio LLC of Southfield and Ablative Solutions Inc. of Kalamazoo, will share the innovator of the year award at Medical Main Street's first medical device conference — called Inno-vention 2012 — Oct. 3-5 at the Royal Park Hotel in Rochester.

Ablative Solutions uses catheters to damage nerve fibers that pass from the brain to the kidney. The damaged nerves send fewer signals in sick patients, which lowers blood pressure and can treat hypertension and congestive heart failure. A prototype device has proved proof of principle, and human trials are expected to begin in the second quarter next year.

Ablative Solutions' CEO is Tim Fischell, M.D., a professor of medicine at Michigan State University and the medical director of the Borgess Heart Institute's department of cardiovascular research in Kalamazoo. more


MAF-1 Managing Director featured in Innovation Talk segment

July 31, 2012 - WGVU Public Radio

Innovation Talk with Patrick Center: Michigan Accelerator Fund 1 finances primarily life science, advanced manufacturing and homeland security ideas. What do inventors and entreprenuers need to know before presenting their ideas to fund investors? Listen to Dale Grogan, MAF-1 Managing Director, share his thoughts in this WGVU public radio feature story. more


Researchers study potential new therapeutic target for Alzheimer's disease

June 21, 2012 - MSDC PRESS RELEASE

Physicians at medical centers in Kalamazoo and Grand Rapids are helping to identify interested individuals for participation in a clinical trial of a novel drug therapy for patients with dementia due to Alzheimer’s disease. MSDC-0160, a new drug which is also being developed as a treatment for diabetes by Kalamazoo-based Metabolic Solutions Development Company, LLC (MSDC), modulates mitochondrial metabolism which may play an important role in brain cell survival. more


New Research Suggests Novel Insulin Sensitizer Works Through a New Mechanism to Treat Root Cause of Type 2 Diabetes 

May 29, 2012 – PR Newswire

A study published online in the Journal of Biological Chemistry ( showed a new drug to treat diabetes being developed by MAF-1 portfolio company Metabolic Solutions Development improved insulin resistance and inflammation in obese mice. These findings by researchers at Washington University School of Medicine, in collaboration with colleagues at the University of Michigan and MSDC, suggest that MSDC-0602, a novel anti-diabetic drug which is in Phase 2 clinical trials, may constitute the first in a class of next generation insulin sensitizers that appear to work through a new biochemical mechanism to treat insulin resistance and type 2 diabetes.more

Page 1 ... 3 4 5 6 7 ... 8 Next 10 Entries »